Specialized pro-resolving lipid mediator pathway (SPM pathway)

The **specialized pro-resolving lipid mediator (SPM) pathway** refers to a series of enzymatic processes that generate specialized pro-resolving mediators from polyunsaturated fatty acids such as arachidonic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)[1][4][5]. These mediators include lipoxins, resolvins, protectins, and maresins. The biosynthesis involves enzymes like 5-lipoxygenase (ALOX5), 12-lipoxygenase (ALOX12), 15-lipoxygenase (ALOX15/ALOX15B), cyclooxygenases, and cytochrome P450 monooxygenases[1][4]. SPMs actively orchestrate the resolution phase of inflammation by limiting neutrophil infiltration into tissues, promoting the clearance of apoptotic cells by macrophages (“efferocytosis”), inhibiting further production of inflammatory cytokines, and restoring tissue homeostasis[3][4][5]. While individual SPMs act through specific G protein-coupled receptors such as ALX/FPR2 or GPR32 on immune cells[2], the “SPM pathway” itself is not a single molecular target but rather a collection of metabolic routes producing these bioactive lipids. Preclinical studies suggest that synthetic or stabilized analogues may have therapeutic potential in diseases where chronic inflammation is pathogenic—such as periodontitis, cardiovascular diseases, autoimmune disorders like rheumatoid arthritis or lupus erythematosus, diabetes mellitus types 1 and 2, metabolic syndrome-related conditions including obesity-linked complications, asthma/allergic diseases, psoriasis/skin disorders as well as neurodegenerative syndromes like Alzheimer’s disease[3][4]. However—based on current evidence—the identity and signaling roles for many proposed human SPM receptors remain incompletely validated; quantification in clinical samples is technically challenging due to low endogenous levels; thus their precise physiological relevance in humans remains under debate[1]. The “SPM pathway” should not be considered a discrete druggable target akin to an enzyme or receptor but rather describes an entire class of endogenous anti-inflammatory mechanisms. > "Specialized pro-resolving mediators are a large class... formed in cells by metabolism of polyunsaturated fatty acids... Pre-clinical studies implicate SPM in orchestrating the resolution of inflammation. Prominent members include resolvins and protectins." [4] > "Formation... usually involves arachidonic acid 5-lipoxygenase... different types... Typically formed via consecutive steps oxidation..." [1] **Note:** This entry does not refer to a single molecule/receptor but rather an entire biosynthetic/metabolic network. For structured data purposes it should be flagged as incorrect for use as a canonical drug target name.

Other names

Specialized pro-resolving mediators pathwaySPM biosynthetic pathwayPro-resolution lipid mediator pathway